Medical Device Definition under UK MDR 2002 Regulation 2

1. Key takeaways

The United Kingdom definitions of a medical device and an in vitro diagnostic medical device are set out in regulation 2 of the UK MDR 2002. They are closely modelled on the EU MDR definitions but are not copied word for word. The assessment path runs in two stages: first, the product must meet the intended-purpose elements — diagnosis, prevention, monitoring, treatment, alleviation of disease, compensation for an injury, investigation, replacement or modification of the anatomy or of a physiological process, or control of conception; second, it must not achieve its principal intended action by pharmacological, immunological or metabolic means. Only when both conditions hold does the product fall within the regulatory scope. Getting this two-stage test right matters more than any later step: it decides whether the product enters the device system at all, and every downstream obligation — classification, UKRP appointment, registration and surveillance — exists only for products that pass it.

In operational terms, the two-stage test also disciplines internal discussions about new products. A development team may describe a feature as a wellness function while the marketing team presents it as a diagnostic aid; regulation 2 resolves the conflict by looking to the intended purpose as stated by the manufacturer. For this reason, the definition analysis should be performed on the finalised labelling and claims, not on early concept documents, and it should be repeated whenever the claimed uses change materially. Products that sit genuinely on the boundary — where the contribution of pharmacological, immunological or metabolic action is arguable — should be treated as devices unless and until a documented analysis concludes otherwise, because the cost of treating a device as a non-device is an unlawful placing on the market, while the cost of the opposite error is only a modest additional compliance effort.

2. Legal basis

The definition provisions are compact, and the official guidance points directly to them:

• UK MDR 2002 (SI 2002/618, as amended): regulation 2 (interpretation), which contains the definitions of a medical device and of an in vitro diagnostic medical device.
• Official guidance: the GOV.UK page Register medical devices to place on the market sets out the regulation 2 definitions in full and directs readers who are uncertain to the MHRA guidance Borderline products: how to tell if your product is a medical device.

Because the definitions live in the interpretation provision rather than in a dedicated scope chapter, they are easy to overlook when a company reads the regulation for the first time. Locating regulation 2 and working through its elements clause by clause should be the opening exercise of every United Kingdom project, before any classification or registration work is begun.

3. Expert insights

Insight 1: software is written into the definition in express terms. The device definition in regulation 2 includes the word software, and extends further to software intended by the manufacturer to be used specifically for diagnostic or therapeutic purposes and necessary for its proper intended application. This means that software as a medical device (SaMD) and software that accompanies a device can both constitute devices in the United Kingdom; the test is the manufacturer’s intended purpose, not the form of delivery. A programme sold as a standalone app and a programme bundled with hardware may therefore carry the same regulatory status if their intended purposes coincide, and marketing language that downplays a diagnostic or therapeutic function will not change the legal analysis.

Insight 2: the IVD definition excludes products for general laboratory use. The IVD definition in regulation 2 expressly covers specimen receptacles, but excludes products for general laboratory use, unless, by virtue of their attributes, the manufacturer specifically intends them for in vitro diagnostic examination. That unless clause is the watershed for reagent products: the same bottle of buffer solution can sit on opposite sides of the regulatory line depending on what the manufacturer states about its intended use. Labelling and product claims therefore carry direct legal consequences for IVDs, in a way that purely technical documentation does not.

Insight 3: the definition analysis must precede the classification analysis. The most common upstream error among companies entering the United Kingdom is to skip the definition question and move straight to classification. If a product is not a device at all, classification, UKRP appointment and registration obligations never arise; conversely, if a product is misjudged as a non-device while in fact falling within the definition, placing it on the market amounts to an unlawful placing without the required compliance steps. The order of operations is not stylistic — it determines whether the rest of the project has a legal foundation.

4. Practical recommendations

GRZAN recommends preparing a definition determination memorandum for every borderline product, working through the intended-purpose elements and the exclusions of regulation 2 item by item, and citing the MHRA Borderline products guidance as corroborating authority. For products whose intended purpose may shift with marketing materials, the evidence chain should include the instructions for use, the labelling, website copy and exhibition materials together, because United Kingdom enforcement practice attaches weight to the uses the manufacturer publicly claims. The memorandum should be reviewed whenever any of those materials changes, so that a marketing revision cannot silently move a product into or out of the device definition without a fresh legal assessment.

5. Verification checklist

• □ The intended-purpose elements of regulation 2 have been assessed item by item
• □ The principal intended action has been confirmed as not pharmacological, immunological or metabolic
• □ Software products have been assessed against the device definition
• □ Reagent products have been assessed against the general laboratory use exclusion
• □ The determination memorandum has been archived and publicly claimed uses reviewed at the same time

Legal information verified as of 29 October 2026.

GRZAN supports manufacturers with the following services for the United Kingdom market:

• Appointment of the UK Responsible Person (UKRP) and signature support for the letter of authorisation
• End-to-end MHRA registration (DORS) filing and account lifecycle management
• Device classification determination, GMDN code selection and annual registration fee estimation
• Dual-track design for Great Britain and Northern Ireland, including UK(NI) solutions
• Post-market surveillance (PMS) system setup, PMSR/PSUR preparation and vigilance report submission
• Emergency response to serious incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory changes and compliance gap assessment

GRZAN provides end-to-end MHRA registration and compliance support for manufacturers entering the United Kingdom market, covering every stage from market entry planning through post-market obligations. For enquiries, contact info@grzanglobal.com.